Pharming Group N.V.

Pharming Group N.V. (AMS:PHARM) Pharming to receive significant milestone and royalty payments

Pharming Group N.V. (AMS:PHARM) Significant progress with lead product Rhucin®

Pharming Group N.V. (AMS:PHARM) Leiden, The Netherlands, October 13, 2008. Biotech company Pharming Group NV ("Pharming" or "The Company") (Euronext: PHARM) announced today the appointment of Dr Sijmen de Vries as Chief Executive Officer (CEO) of Pharming. This decision was taken by the Shareholders at an Extraordinary Meeting (EGM) held earlier today. Dr de Vries will take up his position as of November 3, 2008 as successor to Dr Francis J. Pinto who will retire at the next Annual General Meeting of Shareholders (AGM) of the Company in 2009. Until then, Dr Pinto will stay on as Non-Executive Chairman of the Management Board to ensure a smooth transition.

Pharming Group N.V. (AMS:PHARM) Dr Pinto to retire after completion of transition period

Pharming Group N.V. (AMS:PHARM) Database for Rhucin® Significantly Expanded

Pharming Group N.V. (AMS:PHARM) Leiden, The Netherlands, September 17, 2008. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it will present at the UBS Global Life Sciences Conference (September 22-25, 2008) in New York.

Pharming Group N.V. (AMS:PHARM) Leiden, The Netherlands, September 3, 2008. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) announced today that the US Food and Drug Administration (FDA) has authorized a clinical study with recombinant human C1 inhibitor (rhC1INH) for the treatment of antibody-mediated rejection (AMR) in kidney transplantation. Dr. Hans Sollinger of the University of Wisconsin, Madison will conduct the clinical trial with rhC1INH under an Investigator IND from the FDA.

Pharming Group N.V. (PINKSHEETS: PHGUF) Leiden, The Netherlands, August 4, 2008. Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) announced today that its inclusion in the Amsterdam Midkap Index (AMX-index) has been confirmed by NYSE Euronext.

Pharming Group N.V. (PINKSHEETS: PHGUF) Regulatory filings moving forward with positive results from clinical studies with Rhucin®

Pharming Group N.V. (PINKSHEETS: PHGUF) Leiden, The Netherlands, July 15, 2008. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) announced today that it has signed a commercialization and supply agreement with Aslan Group A.S. in Turkey ("Aslan") for the marketing and distribution of food or food supplements containing Pharming's human lactoferrin product (hLF).